Merck, NanoBio ink RSV, flu deal; Incoming Princeton freshmen to be offered Novartis' Bexsero;

> Ann Arbor, MI-based NanoBio has signed a licensing agreement with Merck ($MRK) to produce an RSV vaccine and a flu vaccine. More

> About 1,300 incoming Princeton students will be eligible to receive Novartis' ($NVS) meningitis B vaccine Bexsero--unapproved in the U.S.--following an outbreak on campus last year. Report

> The GAVI Alliance has joined with UNICEF and WHO to offer a rotavirus vaccine in Cameroon. More

> Inovio Pharmaceuticals ($INO) has appointed E.J. Brandreth as VP of Quality. Release

> Researchers at Iowa State University have created the first heat-resistant "nanovaccines" to help vaccinate those in developing countries. Report

> The FDA has expanded the age indication for Sanofi's ($SNY) Tdap vaccine by one year to include 10-year-old children. Release

> WHO has declared the South-East Asia region polio-free. Announcement

> Takeda has won Japanese approval for two pandemic flu vaccines. More

And Finally... Merck is using cloud-based computing to speed up vaccine data analysis for faster development. More

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.